Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis

被引:157
作者
Guegan, Sarah
Bastuji-Garin, Sylvie
Poszepczynska-Guigne, Ewa
Roujeau, Jean-Claude
Revuz, Jean [1 ]
机构
[1] Univ Paris 12, Hop Henri Mondor, APHP, Dept Dermatol,Serv Dermatol, F-94010 Creteil, France
[2] Univ Paris 12, Hop Henri Mondor, APHP, Dept Publ Hlth, F-94010 Creteil, France
关键词
D O I
10.1038/sj.jid.5700068
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
The SCORTEN, calculated within 24 hours of admission, is a severity-of-illness score validated for toxic epidermal necrolysis and Stevens-Johnson syndrome. Our purpose was to assess the performance of successive SCORTEN during the first 5 days of hospitalization and to determine the influence of admission delay. Charts of 144 patients aged 46.8 years (719.7), admitted to our department (1993-2003) with Stevens-Johnson syndrome or toxic epidermal necrolysis, were reviewed. Successive SCORTEN were compared between deceased patients (n=28, 19.4%) and survivors (n=116). The performance of the score (calibration, discrimination) was assessed on days 1-5. All seven SCORTEN variables, on days 1-5, were associated with a higher mortality rate. The SCORTEN rose slightly during hospitalization, with a significant difference between days 1 and 4 (< 0.05). Performance of the SCORTEN was good on each day, but slightly better on day 3. The areas under the receiver-operating characteristic curves were above 80%. The admission delay did not differ between deceased patients and survivors. Delay-adjusted SCORTEN was close to the crude SCORTEN. The SCORTEN performance during the first 5 days of hospitalization was excellent, and at its best on day 3. We recommend to compute again the SCORTEN on day 3. The admission delay did not influence prognosis or SCORTEN.
引用
收藏
页码:272 / 276
页数:5
相关论文
共 14 条
[1]
Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis - A prospective noncomparative study showing no benefit on mortality or progression [J].
Bachot, N ;
Revuz, J ;
Roujeau, JC .
ARCHIVES OF DERMATOLOGY, 2003, 139 (01) :33-36
[2]
SCORTEN: A severity-of-illness score for toxic epidermal necrolysis [J].
Bastuji-Garin, S ;
Fouchard, N ;
Bertocchi, M ;
Roujeau, JC ;
Revuz, J ;
Wolkenstein, P .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (02) :149-153
[3]
CLINICAL CLASSIFICATION OF CASES OF TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME, AND ERYTHEMA MULTIFORME [J].
BASTUJIGARIN, S ;
RZANY, B ;
STERN, RS ;
SHEAR, NH ;
NALDI, L ;
ROUJEAU, JC .
ARCHIVES OF DERMATOLOGY, 1993, 129 (01) :92-96
[4]
Toxic epidermal necrolysis: Does immunoglobulin make a difference? [J].
Brown, KM ;
Silver, GM ;
Halerz, M ;
Walaszek, P ;
Sandroni, A ;
Gamelli, RL .
JOURNAL OF BURN CARE & REHABILITATION, 2004, 25 (01) :81-88
[5]
CAMPIONE E, 2000, ACTA DERM-VENEREOL, V32, P430
[6]
THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36
[7]
NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[8]
LARVIN M, 1989, LANCET, V2, P201
[9]
A REVIEW OF GOODNESS OF FIT STATISTICS FOR USE IN THE DEVELOPMENT OF LOGISTIC-REGRESSION MODELS [J].
LEMESHOW, S ;
HOSMER, DW .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1982, 115 (01) :92-106
[10]
SEVERE ADVERSE CUTANEOUS REACTIONS TO DRUGS [J].
ROUJEAU, JC ;
STERN, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (19) :1272-1285